Labcorp Holdings Inc. has underperformed the Nasdaq Composite over multiple time frames, even after reporting first-quarter results that beat expectations. The company's shares have declined 4.1% over the past three months, while the Nasdaq gained 15.8% in the same period. On a year-to-date basis, Labcorp rose 3.5% versus the Nasdaq's 12% gain, and over the past 52 weeks it climbed marginally compared to the Nasdaq's 33.3% return. The stock has been trading below its 50-day and 200-day moving averages since early March. In its first quarter, Labcorp posted adjusted earnings per share of $4.25 on revenue of $3.54 billion, surpassing analyst forecasts of $4.09 and $3.50 billion respectively, and it guided full-year adjusted EPS in the range of $17.70 to $18.35. Wall Street analysts remain bullish with a consensus Strong Buy rating and a mean price target of $311.12, implying a potential upside of 19.9% from current levels.
Laboratory Corporation of America HoldingsQ1 earnings beat and raised guidance
Quest Diagnostics Incorporated